新辅助化疗乳腺癌患者靶控输注依托咪酯意识消失时效应室靶浓度的EC50

目的 测定新辅助化疗后患者靶控输注(target-controlled infusion,TCI)依托咪酯意识消失时的半数效应室靶浓度(EC50).方法 90例ASA Ⅰ或Ⅱ级,同时期行乳腺癌切除手术的乳腺癌患者,根据术前是否接受新辅助化疗以及化疗方案分为未化疗组(Ⅰ组),紫杉醇化疗4周期组(Ⅱ组),药物联合化疗4周期...

Effcet-site EC50 for etomidate by target-controlled infusion at loss of consciousness in breast cancer patients who accepted adjuvant chemotherapy

Objective To determine the Effcet-site EC50 of etomidate to cause loss of consciousness in patients who accepted adjuvant chemotherapy. Methods According to the therapeutic method before their operation,ninety breast cancer patients undergoing elective operations were allocated to 3 groups:non-adjuvant chemotherapy group (group Ⅰ ,n=30),Taxol group (group Ⅱ ,n=30),Adriamycine+Cyclophosphamide+5-Fu group (group Ⅲ ,n=30). TCI etomidate was given by"up and down "method for 10 min in each group. The ration of two close effect-site concentrations was 1.25. Record the state of consciousness of each patient.Results The EC50 in non-adjuvant chemotherapy group was 0.58 mg/L,the 95% confidence level was 0.53 mg/L～0.63 mg/L. The EC50 in Taxol group was 0.34 mg/L,the 95% confidence level was 0.32 mg/L～0.37 mg/L. The EC50 in non-adjuvant chemotherapy group was0.35μg/ml,the 95% confidence level was0.32 mg/L～0.39 mg/L.Conclusion The EC50 of etomidate to cause loss of consciousness in adjuvant chemotherapy group is low than control group.